Sozialstiftung Bamberg — Clinical Trial Site

20 Registered trials

12 Currently recruiting

Organisation

Sozialstiftung Bamberg

Location

Bamberg, Germany

Identifier

ORG-100043498

Address

Buger Strasse 80, Berg, 96049, Germany

Departments

Deparment of Internal and Integrative Medicine
Department of Internal and Integrative Medicine
Gynäkologie
Gynecology
Hämatologie/Onkologie
Hematology and Oncology
Klinik für Frauenheilkunde und Geburtshilfe
Klinik für Integrative Medizin und Naturheilkunde
Klinikum Bamberg – Brustzentrum
Medizinische Klinik III: Nieren- und Hochdruckkrankheiten, Rheumatologie, Akutgeriatrie
Medizinische Klinik V
Medizinische Klinik V; Hämatologie und Internistische Onkologie
N/A
Praxis für Rheumatologie
Sozialstation Bamberg
Sozialstiftung Bamberg Klinikum Bamberg
Sozialstiftung Bamberg, Klinikum am Bruderwald
Zentrum für Innere Medizin, Med. Klinik V, Hämatologie und internistische Onkologie

Clinical trials at this site (20)

Search interface

A study to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in participants aged 18 years and o… Pending

2025-523117-28-00 Relapsed or Refractory Multiple Myeloma 4
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer-… Recruiting

2023-509292-17-00 primary high-risk lobular breast cancer 4 2024-11-08
A trial to evaluate the efficacy and safety of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) in patients with mild to moderate… Recruiting

2024-510807-13-00 ulcerative colitis 10 2024-09-12
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting

2023-506150-21-00 Celiac Disease 4 2024-05-29
Venetoclax plus azacitidine versus standard intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and NPM1 m… Recruiting

2024-515267-59-00 Acute myeloid leukemia 4 2024-04-07
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi… Recruiting

2022-501187-18-00 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise 5 2023-04-24
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
Controlled clinical trial to investigate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhoea-dominant irr… Recruiting

2024-514383-61-00 Diarrhoea predominant irritable bowel syndrome 6 2020-07-07
Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with li… Recruiting

2024-512104-19-00 Irritable Bowel Syndrome 6 2019-11-19
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended

2024-517356-35-00 Moderately Active Rheumatoid Arthritis 4 2025-07-29
Multicenter, prospective, double-blind, randomized, three-armed, placebo-controlled study of long-term therapeutic transfer of encapsulated … Ended

2024-517132-22-00 active ulcerative colitis 5 2023-01-26
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i… Ended

2023-509859-13-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-11-09
This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended

2023-505628-67-00 Relapsed and Refractory Follicular Lymphoma 5 2022-10-28
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
Menthacarin® in the treatment of functional gastrointestinal disorders Ended

2022-501800-92-00 functional gastrointestinal disorders 6 2023-05-15
Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended

2022-502040-13-00 High-risk Myelodysplastic neoplasia 4